Jaap Boelens – VJRegenMed

Importance of international harmonization in cell & gene therapies

admin_vjr_user — Thu, 24 Jun 2021 17:15:39 +0000

Jaap Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on the importance of international harmonization and consensus within the field of cell and gene therapies and how this can help drive the field forward. Dr Boelens highlights the importance of harmonising the eligibility criteria, monitoring standards and outcome measures of early phase clinical trials to allow better comparison of data and to help with the earlier identification of therapeutic solutions most likely to succeed in later phase clinical trials. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

ISCT 2021 highlights: BMT, gene therapy & lymphodepletion

admin_vjr_user — Thu, 24 Jun 2021 17:15:35 +0000

Jaap Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, offers some highlights in stem cell engineering and bone marrow transplantation (BMT) at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021. Dr Boelens describes a plenary session exploring the latest data and considerations in gene therapy and BMT for the treatment of hemoglobinopathies, as well as a international debate on the use of different transplant platforms. In addition, he discusses a plenary focused on lymphodepletion, its impact on the efficacy and toxicity of chimeric antigen receptor (CAR) T-cell therapy and data on the pharmacokinetics of these agents. This interview took place during the ISCT Annual Meeting 2021.

Identifying early predictors of neurotoxicity following CAR-T infusion

admin_vjr_user — Thu, 24 Jun 2021 17:15:33 +0000

Jaap Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, describes a recent study that aimed to detect early recipient predictors of neurotoxicity following CAR-T infusion, which remains a significant challenge. Serum samples from 79 patients with pre-B cell leukemia that had received CD19-directed CAR T-cell therapy were screened using an OLINK-proteomic platform, which led to the identification of several neuroprotective analytes. These recipient markers offer the potential to predict risk of neurotoxicity following CAR T-cell infusion and could enable the development of preventative strategies. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.